Arbutus Biopharma
ABUS
ABUS
88 hedge funds and large institutions have $227M invested in Arbutus Biopharma in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.58M
3.03% more ownership
Funds ownership: 40.32% → 43.35% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
88
Holding in Top 10
1
Calls
$1.82M
Puts
$1.58M
Top Buyers
| 1 | +$11.6M | |
| 2 | +$4.7M | |
| 3 | +$3.49M | |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$3.24M |
| 5 |
Morgan Stanley
New York
|
+$2.74M |
Top Sellers
| 1 | -$10.2M | |
| 2 | -$3.87M | |
| 3 | -$2.48M | |
| 4 |
Renaissance Technologies
New York
|
-$1.91M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.71M |